Clinical characteristics of 210 myeloma patients from the Arkansas cohort, stratified by RHAMM expression below or above the median level for the cohort (dubbed “low” or “high” expression)
Factor . | Overall, no./total no. (%) . | Low expression, no. (%) . | High expression, no. (%) . | P . |
|---|---|---|---|---|
| Age, 65 y or older | 28/210 (13) | 14/105 (13) | 14/105 (13) | 1.000 |
| White | 186/210 (89) | 93/105 (89) | 93/105 (89) | 1.000 |
| Female | 84/210 (40) | 48/105 (46) | 36/105 (34) | .091 |
| Kappa | 124/196 (63) | 60/98 (61) | 64/98 (65) | .553 |
| Lambda | 72/196 (37) | 38/98 (39) | 34/98 (35) | .553 |
| IgA isotype | 48/195 (25) | 25/102 (25) | 23/93 (25) | .971 |
| β2M, 4 mg/L (340 nM) or higher | 77/210 (37) | 40/105 (38) | 37/105 (35) | .667 |
| Creatinine, 2 mg/dL (176.8 μM) or higher | 21/210 (10) | 8/105 (8) | 13/105 (12) | .250 |
| LDH elevated 190 UI/L or higher | 67/210 (32) | 23/105 (22) | 44/105 (42) | .002* |
| Albumin below 35 g/L | 31/210 (15) | 12/105 (11) | 19/105 (18) | .173 |
| HGB below 100 g/L | 57/210 (27) | 32/105 (30) | 25/105 (24) | .277 |
| PCLI 1.0% or higher | 28/184 (15) | 11/91 (12) | 17/93 (18) | .242 |
| BMPC 33% or higher | 107/169 (63) | 56/90 (62) | 51/79 (65) | .753 |
| Cytogenetics abnormalities | 68/191 (36) | 28/94 (30) | 40/97 (41) | .098 |
| CA13 or hypodiploid | 42/68 (62) | 14/28 (50) | 28/40 (70) | .095 |
| Other CA | 26/68 (38) | 14/28 (50) | 12/40 (30) | .095 |
| FISH 13 20% | 88/168 (52) | 42/89 (47) | 46/79 (58) | .153 |
| FISH 13 80% | 46/168 (27) | 23/89 (26) | 23/79 (29) | .635 |
| 1 or more MRI focal bone lesions | 151/193 (78) | 65/93 (70) | 86/100 (86) | .007* |
| 3 or more MRI focal bone lesions | 120/193 (62) | 45/93 (48) | 75/100 (75) | < .001* |
| 1 or more x-ray focal bone lesions | 122/199 (61) | 52/97 (54) | 70/102 (69) | .030* |
| 3 or more x-ray focal bone lesions | 80/199 (40) | 27/97 (28) | 53/102 (52) | < .001* |
Factor . | Overall, no./total no. (%) . | Low expression, no. (%) . | High expression, no. (%) . | P . |
|---|---|---|---|---|
| Age, 65 y or older | 28/210 (13) | 14/105 (13) | 14/105 (13) | 1.000 |
| White | 186/210 (89) | 93/105 (89) | 93/105 (89) | 1.000 |
| Female | 84/210 (40) | 48/105 (46) | 36/105 (34) | .091 |
| Kappa | 124/196 (63) | 60/98 (61) | 64/98 (65) | .553 |
| Lambda | 72/196 (37) | 38/98 (39) | 34/98 (35) | .553 |
| IgA isotype | 48/195 (25) | 25/102 (25) | 23/93 (25) | .971 |
| β2M, 4 mg/L (340 nM) or higher | 77/210 (37) | 40/105 (38) | 37/105 (35) | .667 |
| Creatinine, 2 mg/dL (176.8 μM) or higher | 21/210 (10) | 8/105 (8) | 13/105 (12) | .250 |
| LDH elevated 190 UI/L or higher | 67/210 (32) | 23/105 (22) | 44/105 (42) | .002* |
| Albumin below 35 g/L | 31/210 (15) | 12/105 (11) | 19/105 (18) | .173 |
| HGB below 100 g/L | 57/210 (27) | 32/105 (30) | 25/105 (24) | .277 |
| PCLI 1.0% or higher | 28/184 (15) | 11/91 (12) | 17/93 (18) | .242 |
| BMPC 33% or higher | 107/169 (63) | 56/90 (62) | 51/79 (65) | .753 |
| Cytogenetics abnormalities | 68/191 (36) | 28/94 (30) | 40/97 (41) | .098 |
| CA13 or hypodiploid | 42/68 (62) | 14/28 (50) | 28/40 (70) | .095 |
| Other CA | 26/68 (38) | 14/28 (50) | 12/40 (30) | .095 |
| FISH 13 20% | 88/168 (52) | 42/89 (47) | 46/79 (58) | .153 |
| FISH 13 80% | 46/168 (27) | 23/89 (26) | 23/79 (29) | .635 |
| 1 or more MRI focal bone lesions | 151/193 (78) | 65/93 (70) | 86/100 (86) | .007* |
| 3 or more MRI focal bone lesions | 120/193 (62) | 45/93 (48) | 75/100 (75) | < .001* |
| 1 or more x-ray focal bone lesions | 122/199 (61) | 52/97 (54) | 70/102 (69) | .030* |
| 3 or more x-ray focal bone lesions | 80/199 (40) | 27/97 (28) | 53/102 (52) | < .001* |
RHAMM expression was determined from oligonucleotide microarray experiments on sorted MM PC. P values refer to statistical comparisons between low and high RHAMM expressers; P < .05 are labeled with an asterisk (*).
HGB indicates hemoglobin.